Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

Documenti analoghi

• Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
  di: Hunter, Anthony M., et al.
  Pubblicazione: (2021)
• Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
  di: Talati, Chetasi, et al.
  Pubblicazione: (2020)
• Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
  di: McGraw, Kathy L., et al.
  Pubblicazione: (2016)
• ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
  di: Sallman, David A, et al.
  Pubblicazione: (2017)
• The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
  di: Nazha, Aziz, et al.
  Pubblicazione: (2016)